Pfizer Investor Breakfast at the Cowen and Company 30th Annual Healthcare Conference
Audio Webcast  —
Tuesday, March 9, 2010
7:00 AM E.S.T
Read press release issued March 2, 2010 (PDF)
Download and Print Presentation (1.41 MB) PDF

Pfizer Quarterly Corporate Performance — Fourth Quarter 2009
Audio Webcast  — Conference
call for Analysts and Investors
Wednesday, February 3, 2010
10:00 AM E.D.T.
Read press release issued December 23, 2009 (PDF)
Performance Report — Fourth Quarter 2009
Download and Print Presentation (543 KB) PDF

More Investor Presentations

2009 Corporate Responsibility Report

Part of being a responsible company is operating with transparency. That's why
Pfizer has created a Corporate Responsibility Report to detail our priorities: discovering and developing new medicines, improving access to medicines and partnering to find health system solutions.

View the Interactive 2009 Corporate Responsibility Report

Wyeth Transaction
Important Information for Investors

Access key merger documents 

Effective October 15, 2009 Pfizer Inc. acquired Wyeth in a cash and stock merger. Pursuant to the terms of the merger, Wyeth holders will receive 0.985 of a share of Pfizer Inc. common stock and $33.00, without interest for every 1 share of Wyeth common stock they own as of the effective date. Holders who own their shares in "street name" or with a broker are urged to contact their broker accordingly for further instructions. Registered holders who hold either certificates, book entry shares and/or participate in the Wyeth BuyDIRECT Stock Purchase and Sale Plan dividend reinvest program will receive information in the mail shortly regarding how to exchange their shares.

Access key merger documents 

Working Mother 100 Best Companies

Pfizer has been named among the 2009 Working Mother 100 Best Companies.

View the press release
Visit workingmother.com

Clinical Trial Design,
Human Subject Protection & GCP

Written by the Director of the Clinical Trial Centre at the University of Hong Kong and the President & CEO of the Association for Accreditation of Human Research Protection Programs (AAHRPP), this manual was sponsored by Pfizer to help acquaint new research ethics committee members about clinical trial design, human subject protection, and good clinical practice (GCP) requirements. The manual addresses research ethics and global standards for clinical trials. The author-editors, Professor Johan Karlberg and Dr. Marjorie Speers, reviewed the contents of this manual with a board of leading experts in research ethics.

• Reviewing Clinical Trials: A Guide for the Ethics Committee